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Background: Serum carbohydrate antigen 19-9 (CA 19-9) has been shown to be a sen-
sitive and specific serum marker for pancreatic cancer. Little has been published about
correlations between baseline CA 19-9 level or changes to CA 19-9 level and median over-
all survival (mOS). Its impact on monitoring treatment efficacy remains under discussion,
however.
Methods: CA 19-9 serum level was measured in 181 consecutive patients with advanced
pancreatic cancer (APC) being treated with gemcitabine-based first-line chemotherapy. We
separated the patients into several groups depending on baseline CA 19-9 levels and the
CA 19-9 response after 6–8 weeks of treatment. Evaluations were made using SPSS 19.9.
Results:Median baseline CA 19-9 level was 1,493 U/ml (range 40–1,043,301). Patients with
baseline CA 19-9 ≤1,000 U/ml had a mOS of 14.9 months (95% CI: 11.36:18.44), whereas
patients with CA 19-9>1,000 U/ml had a mOS of 7.4 months [(95% CI: 5.93:8.87) p<0.001,
HR 2.12]. With regard to the change in CA 19-9 after 6–8 weeks of treatment: patients with
increased CA 19-9 levels had a mOS of 8.1 months, those with stabilized CA 19-9 levels
11.6 months, and those with decreased CA 19-9 levels 11.1 months (p<0.019).
Conclusion: CA 19-9 levels can separate patients with differing mortality risks at baseline.
Patients with stabilization or high response of CA 19-9 after 6–8 weeks of treatment had
no significant differences in survival rates, whereas patients with increased CA 19-9 had
significantly lower survival rates, indicating an early treatment failure.
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INTRODUCTION
Despite global advances in oncology, pancreatic cancer is still a
devastating disease with poor prognosis. It remains one of the
leading causes of cancer-related deaths worldwide, reflected by an
incidence of 277,668 new cases and almost the same mortality rate
(266,029 cases) per year (GLOBOCAN, 2008). Due to early dis-
ease symptoms being missed, only up to 20% of patients can have
their cancer resected with curative intent, however, probably due to
early lymphatic spread or micrometastasis, the 5-year overall sur-
vival rate of resected patients is only 15–22% (Neoptolemos et al.,
2004; Oettle et al., 2007; Gillen et al., 2010) in spite of adjuvant
treatment.
The majority of patients presenting with advanced disease have
a 5-year survival rate below 5%. The 1-year survival rate ranges
between 18 and 40% (Burris et al., 1997; Moore et al., 2005; Her-
rmann et al., 2007; Conroy et al., 2011), depending on treatment
design. Current strategy is that patients with better performance
status (0–1) receive combined chemotherapy using a gemcitabine-
based regimen (Louvet et al., 2005; Heinemann et al., 2008;
Pelzer, 2008a; Cunningham et al., 2009) or a gemcitabine-free
combination (Conroy et al., 2011). The majority of patients with a
moderate performance status should be treated with gemcitabine
monotherapy, or in selected cases in combination-therapy with
erlotinib (Moore et al., 2005). The overall benefit of a second-line
therapy was proven in a phase III setting (Pelzer et al., 2011), addi-
tionally many phase II trials have demonstrated moderate efficacy
of several treatment options (Pelzer, 2008b). For individualized
therapy it is important that refractory disease is detected as early
as possible to enable further treatment strategies to be offered and
thus increase the benefit of adopted second-line treatment and
hopefully prevent side effects due to ineffective therapy. Computed
tomography or magnetic resonance imaging are still the reference
methods for evaluating the response to chemotherapy treatment,
but are an expensive and not always reliable assessment method
(Ishii et al., 2005).
Many different biomarkers have been studied in the last decade
in the hope of finding a simpler evaluation tool for physi-
cians. Firstly in order to detect more patients at an early tumor
stage, and secondly in order to determine the efficacy of tumor
treatment so that current treatment strategies can be modified.
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Serum carbohydrate antigen 19-9 (CA 19-9) – first described
by Koprowski et al. (1979) – has been shown to be a sensitive
and specific serum marker for pancreatic cancer (Ballehaninna
and Chamberlain, 2011). About 10% of the general population
are lacking the Lewis blood group antigen and thus are not able
to express the carbohydrate antigen (Lamerz, 1999; Duffy et al.,
2010). We evaluated this proven biomarker in our patients to
investigate the impact of CA 19-9 serum levels on survival.
MATERIALS AND METHODS
For this retrospective analysis we included patients with his-
tologically confirmed advanced pancreatic cancer (APC) from
our outpatient department who were treated with gemcitabine
or gemcitabine-based first-line chemotherapy in our department
between 1998 and 2005. Blood samples had been taken at treat-
ment begin and every 6–8 weeks after and it was possible to follow
up for overall survival.
Patients with a second malignancy or whose bilirubin levels
were higher than the upper normal limit were excluded to avoid
elevated CA 19-9 serum level due to other causes.
Patients were initially separated into two groups depending on
baseline CA 19-9 serum level (≤1,000 vs. >1,000 U/ml) to detect
the assumed prognostic impact of the CA 19-9 serum base line
value. Furthermore, to investigate the predictive impact of the
change of the CA 19-9 serum level within the first 6–8 weeks, we
separated the patients into three groups according to its CA 19-9
serum level response within 6–8 weeks of initial treatment (>50%
decrease in CA 19-9 serum value vs. 50% decrease to 20% increase
vs. >20% increase in CA 19-9 serum value). Median overall sur-
vival (mOS) was defined as the duration between start of treatment
and patient death from any cause. CA 19-9 serum levels were deter-
mined via electrochemiluminescence immunoassay (Elecsys 2010,
Roche Diagnostics, upper normal limit of 37 U/ml).
Categorical variables were described by absolute and relative
frequencies; age and CA 19-9 serum level were reported as median,
ranges, arithmetic averages, and percentages from baseline. The
overall survival was reported as median with 95% confidence inter-
val, discrimination between the subgroups was done using the
log-rank test and the cox proportional-hazard model. The graphic
survival presentation was done using the Kaplan–Meier estimation
(IBM SPSS 19.0).
RESULTS
Two hundred fifty patients were screened and 181 patients were
included in our analysis (Table 1). One hundred fifty (82.9%)
patients had elevated baseline carbohydrate antigen 19-9 level
above the upper limit of normal (>37 U/ml) and were selected
for further specific analysis. Four (12.9%) out of 31 patients had
elevated CA 19-9 serum level 6–8 weeks after treatment start in
spite of normal baseline CA 19-9 serum level. The median serum
level of CA 19-9 in 150 patients was 1,493 (40–1,043,301) U/ml
at treatment begin; median age was 64 (range: 33–101) years.
mOS of the 150 patients with upfront elevated CA19-9 level was
10.5 months (95% CI: 9.10–11.90). Patients with baseline CA19-9
≤1,000 U/ml (n= 66) had a mOS of 14.9 (95% CI: 11.36–18.44),
whereas patients with baseline CA 19-9 serum level> 1,000 U/ml
Table 1 | Patients’ baseline characteristics.
Characteristic
Included patients with pos. CA 19-9 181
Patients with CA 19-9 >37 U/ml at baseline 150
AGE (YEARS)
Median 64
Range 33–101
GENDER (n)
Female 66 (44%)
Male 84 (66%)
STAGE (n)
M0 31 (20.7%)
M1 119 (79.3%)
BASELINE CA 19-9 (U/ml)
Median 1,493
Arithmetic mean 23,488
Range 40–1,043,301
FIRST-LINETREATMENT (n)
Gem 79 (52.7%)
Gem/folinic acid/5-FU 71 (47.3%)
OVERALL SURVIVAL (MONTHS)
Median 10.5
95% CI 9.1–11.9
FIGURE 1 | Median overall survival according to CA 19-9 serum level
baseline level.
(n= 84) had a poorer mOS of 7.4 (95% CI: 5.93–8.87) [log-rank:
p< 0.001; HR 2.12 (95% CI: 1.52–2.96)] (Figures 1 and 3).
CA 19-9 serum level response after 6–8 weeks of treatment was
as follows: patients with decreased CA 19-9 serum level (<50%)
had an mOS of 11.1 months (95% CI: 8.85–13.36), patients with
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FIGURE 2 | Median overall survival according to changes in CA 19-9
level after 6–8weeks of treatment.
FIGURE 3 | Forest plot of interfering CA 19-9 serum level
characteristics.
stabilization of CA 19-9 serum level (ranging from a decrease of
50% to an increase of 20%) had an mOS of 11.6 months (95%
CI: 8.43–14.77), and patients with increased CA 19-9 serum level
(>20%) an mOS of 8.1 months (95% CI: 6.56–9.64) (Figures 2
and 3). Patients older than the median age of 64 years did not have
poorer mOS [10.8 months (95% CI: 9.87–11.73)] than patients
of the median age of 64 years or younger at time of diagnosis
[9.3 months (95% CI: 6.94–11.66), log-rank p= 0.819; HR: 1.04
(95% CI: 0.75–1.44)].
DISCUSSION
This was a non-intervention study, so the retrospective method of
this investigation was appropriate. Former reports about baseline
CA 19-9 serum levels playing an important role in prediction
of overall survival are supported by our findings. Patients with
lower baseline CA 19-9 serum level (≤1,000 U/ml) had signifi-
cantly better mOS than patients with a higher CA 19-9 serum level
(>1,000 U/ml), indicating more aggressive cancer characteristics
or higher cancer burden and thus a higher mortality risk for this
patient group [HR 2.12 (95% CI: 1.52–2.96)] (Figure 1). The CA
19-9 serum level characteristic does not seem to have interaction
with patients age, because there was no difference in mOS for
patients grouped according to a median age of 64 years [HR: 1.04
(95% CI: 0.75–1.44)], indicating that age does not play a significant
role in predicting survival.
The main focus of our work was the investigation of changes
of serum level CA 19-9 after treatment initiation and its impact
on overall survival, similar to other research groups (Ballehaninna
and Chamberlain, 2011), except that the other researchers sepa-
rated the patients only into two groups: response or no response
of CA 19-9 serum level. In this studies, serum marker response
means a decrease of between 20 and 89% of CA 19-9 serum level
(Ballehaninna and Chamberlain, 2011). Results were published
as a positive correlation between response and overall survival.
We tried to find out whether patients with nearly stabilization of
the CA 19-9 serum level had survival disadvantages compared to
those patients with high response of CA 19-9 serum level. Thus
our analysis was conducted with three different types of CA 19-
9 serum level response: in the first group there was a decrease of
more than 50%, in the second group with stabilization the response
ranged from a decrease of 50% to an increase of 20%, and in the
third group there was an increase of more than 20%. Our findings
showed that patients with a high CA 19-9 serum level response
did not have higher overall survival than patients with stabilized
CA 19-9 serum level [HR 1.04 (95% CI: 0.7–1.52)]. Patients who
are CA 19-9 serum levels increased by more than 20% had signif-
icantly shortened overall survival in comparison to patients with
stabilized CA 19-9 serum level [1.7 (95% CI: 1.12–2.6)] (Figures 2
and 3). This implies that an increase in CA 19-9 serum levels
of more than 20% after 6–8 weeks of treatment is indicative of an
early treatment failure requiring a different antineoplastic regimen
if available. In contrast, patients with greatly decreased CA 19-9
serum levels or stabilization might benefit from continuing the
regimen. This is remarkable because few research groups assumed
that all patients with no CA 19-9 serum level response (e.g.,
less than 20% decrease) should change to second-line treatment
because of resistance to first-line therapy.
The correct timepoint for predictive CA 19-9 serum level mea-
surement has often been discussed. We chose the point between
week 6 and 8 of treatment because of the inconsistent amount
of this serum marker in the first 4–6 weeks after treatment begin.
Thus – similar to other research groups (Vormittag et al., 2009) –
we observed elevated CA 19-9 serum levels within the first weeks
of treatment in patients with further decline of this biomarker in
our own clinical experience.
CONCLUSION
Our findings support the importance of monitoring treatment
response with carbohydrate antigen 19-9 as a surrogate marker. In
summary we advise that patients with decreased and stabilized CA
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19-9 serum levels after 6–8 weeks of treatment continue the same
first-line treatment regimen, whereas patients with an increase
in CA 19-9 serum level of more than 20% should switch to
second-line treatment depending on current performance status.
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